Imperial College London

ProfessorRobinShattock

Faculty of MedicineDepartment of Infectious Disease

Chair in Mucosal Infection and Immunity
 
 
 
//

Contact

 

+44 (0)20 7594 5206r.shattock

 
 
//

Location

 

453Wright Fleming WingSt Mary's Campus

//

Summary

 

Guest Lectures

Chair of Scientific Advisory Board for the International Partnership on Microbicides (ongoing).

Member of the Global HIV Vaccine Enterprise Scientific Committee (2007-2008)

Chair of the WHO-UNAIDS HIV Vaccine Initiative Advisory Committee (2011-2014)

Lead PI of the Mucosal Discovery Team for the Center for HIV/AIDS vaccine Immunology consortium (ongoing).

Member of Scientific Advisory Committee (SAC) for the South African AIDS Vaccine Initiative of the Medical Research Council of South Africa (2008-2012).

Member of Scientific Advisory Board (SAB) for the International AIDS Vaccine Initiative (IAVI) (2010-ongoing).

Member of Scientific Advisory Committee (SAC) for the Chinese HIV Vaccine Initiative (CAVI) (2010-2012).

Member of the Board of Directors of the La Jolla Foundation for Microbicide Research (ongoing) http://www.lajollafoundationformicrobicidesresearch.org/

Co-Chair of the 1st HIV Research for Prevention international meeting (replacing the AIDS Vaccine and microbicides meetings (October 2014 South Africa)

Member of scientific organizing committee for the International Microbicides Conference (2000, 2002, 2004, 2006, 2008, 2010).

Member of scientific organizing committee for the International AIDS Vaccine  Conference (2009, 2010).

Member of Scientific Working Group of the Rockefeller Foundation's Microbicides Initiative (USA) (2001, 2005).

Member of the NIH Microbicide Research Planning Committee, FY 2004, 2005 2006, 2007 NIH Plan for HIV-Related Research.

Member of the Review of Research Using Non-Human Primates Panel chaired by Professor Sir Patrick Bateson (2011)

 

Guest Lectures

A shot in the arm towards effective HIV vaccines., TRON, Johannes Gutenberg University, Mainz, Germany, 2014

AIDS Vaccine Clinical Trials., Hong Kong University, Pasteur Virology Course, China, 2013

Optimising Humoral Responses for HIV Prevention., Elsinore Meeting on Infection Immunity, Elsinore, Denmark, 2013

Vaccine Approaches to Optimise Antibody Responses to HIV., University of Cape Town, South Africa, 2013

Multipurpose prevention technologies: innovative approaches for prevention of sexual transmitted and reproductive tract infections and contraception., Invited presentation as part of the 40 years of innovation in Reproductive Health: the UNDP, UNFPA, WHO, World Bank Special Program for Research, Development and Research Training in Human Reproduction (HRP) at the XX FIGO World Congress of Gynecology and Obstetrics., Rome, Italy, 2012

Vaccine Approaches to Optimize Humoral Mucosal Immunity to HIV-1, HIVACAT Symposium, Institute for AIDS Research, IrsiCaixa, Barcelona, Spain, 2012

Optimising vaginal protection against HIV-1 infection., HIV Grand Rounds from the Perelman School of Medicine. University of Pennsylvania, Philadelphia, USA., 2012

The Current State of Mucosal Immunity Elicited by Vaccines, AIDS Vaccine Conference 2012, Boston, USA, 2012

Optimising mucosal responses to candidate HIV vaccines., 2012 CFAR Annual Conference: AIDS Pathogenesis, Prevention & Cure. Case Western Reserve University, Cleveland, USA, 2012

Vaccine-Microbicide combination studies in NHPs, Mucosal Responses in the Context of Combined HIV-1 Prevention Strategies Meeting. National Institute for Health., Maryland, USA, 2012

Recent advances in HIV vaccine and microbicide research, Paul Ehrlich Institute, Germany, 2012

HIV vaccines, moving beyond the RV144 Thai trial, Health Protection Agency, Porton Down, UK., 2012

Mucosal vaccine strategies to promote humoral immunity to HIV-1, 2nd Annual Vaccines Congress, London, UK, 2012

Combination Microbicides, M2012 Pre Conference Workshop - The Mucosal Biology of Sexually Transmitted Infection: Translating Basic Science into Novel HIV Interventions. Microbicides 2012 Conference., Sydney, Australia, 2012

Updates on the HIV Vaccine., 4th National Conference on Current Issues in Sexual Health., London, UK, 2012

Global Health as a Societal Challenge. Horizon 2020 – The Framework Programme for Research and Innovation. Committee on Industry, Research and Energy Hearing., European Parliament, Brussels, 2012

Optimising vaginal humoral responses to HIV-1., National Institute of Health Vaccine Center, Bethesda, USA., 2012

A paraclinical approach to HIV vaccine research., Royal College of Physicians, Advanced Medicine Meeting, London, UK, 2012

Human Immunodeficiency Virus, Royal Society of Medicine, Spotlight on Infectious Diseases Meeting, London, UK, 2012

HIV Vaccines & Microbicides, Infectious Diseases Research Network, London, UK, 2011

Efficacy of Non-Neutralizing Antibodies in NHP, AIDS Vaccine Conference 2011, Bangkok, Thailand, 2011

The combined approach to preventing HIV infection (Plenary), International AIDS Society Conference on HIV Pathogenesis, Treatment & Prevention., Rome, 2011

Anticipating effective microbicides, Karolinska Institute - 30 Years of AIDS Conference, Stockholm, 2011

Vaccine strategies for focusing humoral immune response on the mucosal portal of HIV entry, Jenner Institute, University of Oxford, Oxford, UK, 2011

Combining Prevention Technologies: Vaccines and Microbicides, Keystone HIV Symposia, Whistler, Canada, 2011

Focusing humoral immune response on the mucosal portal of HIV entry, SSI Centre for Vaccine Research, Copenhagen, Denmark, 2011

Blocking acquisition across mucosal surfaces, AIDS Vaccine Conference, Atlanta, USA, 2010

Understanding mucosal immunity and HIV transmission: the way to new prevention technologies, XVIII International AIDS Conference, Vienna, Austria, 2010

Current Progress on Vaccines and Microbicides, Wuhan Institute of Virology, Chinese Academy of Science, Wuhan, China, 2010

Induction of mucosal immunity to HIV, Europrise workshop of humoral immunity to HIV, Milan, Italy, 2010

The state of the ART for microbicides, Plenary at International Microbicides Meeting, Pittsburgh, USA, 2010

Sites of delivery for mucosal vaccines, NIH workshop on HIV and mucosal immunity, Dartmouth Medical School, USA, 2010

Optimising Vaginal Immunity to CN54 gp140, Chinese AIDS Vaccines Initiative Annual Conference, Shanghai, China, 2010

B cells and mucosal immunity: neutralizing antibodies and Fc mediated function, WHO Scientific Briefing on "The State of the Art in HIV Vaccine Science and its Implications for Clinical Trial Design", Johannesburg, South Africa, 2010

Progress towards new HIV prevention options - vaccines and microbicides, Society for General Microbiology, Edinburgh, UK, 2010

Vaccines and microbicides? Getting the best from new prevention technology, CONRAD annual consortium meeting, Wsahington DC, USA, 2010

Current Progress in the Development of Effective Microbicides, Joint US-Russian summit on HIV treatment and prevention, Moscow, Russia, 2009

AIDS Vaccine Research: sustaining progress in a changing prevention landscape, International AIDS Vaccine Meeting, Paris, France, 2009

Vaccines and microbicides? Getting the best from new prevention technology, EUROPRISE Consortium Meeting, Budapest, Hungary, 2009

Protection Against HIV in the Urogentical Tract, International Mucosal Immunology Meeting, Boston, USA, 2009

Measuring mucosal immune responses to HIV encelope vaccines, NIH Mucosal Workshop, Wsahington DC, USA, 2009

Creating Barriers to mucosal HIV infection: Chemical, Innate and Adaptive, American Society for Reproductive Immunology, Orlando, USA, 2009

HIV/AIDS: Back to square one? Progress towards treatment and prevention., European Commission - Research Directorate, Challenges for the future: Research on HIV/AIDS, Malaria and TB, Brussels, Belgium, 2008

Vaccines and microbicides? Getting the best from new prevention technologies, International AIDS Society Meeting, Cape Town, South Africa, 2008

New developments in design of effective microbicides, Keystone meeting on HIV pathogenesis, Banff, Canada, 2008

Novel antigen design and delivery for sustained mucosal protection against HIV-1 infection, Keystone Vaccines Meeting, Cape Town, South Africa, 2007

Mucosal immunity and HIV vaccines, AIDS Vaccine Conference, Seattle, USA, 2007

Mucosal protection to HIV-1: what to induce and how to measure it?, AIDS Vaccine 2007, Seattle, USA, 2007

Current progress is microbicide development, 4th IAS Conference on HIV Pathogenesis and Treatment, Sydney, Australia, 2007

Overview of Microbicide Development, IAS Conference on HIV Pathogenesis and treatment, Toronto, Canada, 2006

Microbicides and vaccines - competing bed fellows or possible partners?, International Microbicides Meeting, Cape Town, South Africa, 2006

Microbicides, Plenary talk at CROI, San Francisco, USA, 2006

Sexual trauma and the female genital tract, 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, 2005

Vaginal Microbicides, current state of progress, 16th German and 10th Austrian AIDS Conference, Vienna, Austria, 2005

Vaginal Microbicides to prevent HIV-1 transmission, Plenary at Spanish National AIDS Conference, Madrid, Spain, 2004

Microbicides - looking forward, MDP Investigators Meeting, Tanzania, 2004

Sexual transmission of HIV: from mechanisms to microbicides, European Mucosal Immunology Group, Lyon, France, 2004

Preventing HIV-1 infection, Caledonian Royal Society of Edinburgh, Edinburgh, UK, 2004

Matching mechanisms with microbicides, Plenary talk at Microbicides Conference, London, UK, 2004

How near are we to an effective microbicide, Plenary at 11th Conference on retroviruses and Opportunistic Infections, San Francisco, USA, 2004

Microbicides: the basic science, Aaron Diamond AIDS research centre, New York, USA, 2003

Microbicides: Aids to safe sex, Distinguished scholars program, Department of Pharmacology, Queens University Belfast, Belfast, NI, 2003

Viral and non viral targets, the need for combinations, Alliance for Microbicide Development, Washington DC, USA, 2003

HIV infection of monocyte and macrophages, chemokines and their receptors, Royal Society of Medicine, London, UK, 2002

Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue, National Institute for Health, Bethesda, USA, 2002

HIV infection of the female genital tract: matching mechanisms with topical prophylaxis, San Raffaele Scientific Institute, Milan, Italy, 2002

Opportunities and challenges in pre-clinical and clinical research, XIV International AIDS Conference, Barcelona, Spain, 2002

Human cultures for assessing microbicides, Population council and Rockefeller Foundation Symposium on Microbicides, Barcelona, Spain, 2002

Nonoxynol-9: Lessons in vitro, Microbicides 2002 Conference, Antwerp, Belgium, 2002

Nonoxynol 9: Lessons in vitro, Microbicides 2002 Conference, Antwerp, Belgium, 2002

Ex vivo cultures for assessing microbicides, Microbicides 2002 Conference, Antwerp, Belgium, 2002

Microbicide combinations: the way forward, Division of Infectious Diseases, Mount Sinai School of Medicine, New York, USA, 2002

Development of attachment/fusion inhibitors as topical microbicides against HIV infection, Alliance for Microbicide Development Meeting, Washington, USA, 2002

Ex vivo cervical explants, a model of HIV transmission, NIH relevancy of experimental models to HIV disease meeting, Puerto Rico, 2001

HIV transmission and preventative strategies, Wuhan Institute of Virology, Chinese Academy of Medicine, Wuhan, China, 2001

HIV transmission and preventative strategies, Institute of Virology, Chinese Academy of Medicine, Beijing, China, 2001

Rectal explant culture, a model of HIV transmission through anal intercourse, NIAID Rectal Microbicides Workshop, Baltimore, USA, 2001

Viral Replication and quasispecies distribution after mucosal immune activation in HIV-infected individuals, European Conference on Experimental AIDS Research, Edinburgh, UK, 2001

Preclinical development of topical microbicides: target selection and lead generation, National Institute of Allergy & Infectious Diseases, Prevention Strategy Branch, Washington, USA, 2001

Entry and inhibition: modeling sexual HIV transmission of HIV infection, Henry Vogt Cancer Research Institute, University of Louisville School of Medicine, Louisville, USA, 2001

HIV infection of the female genital tract: mechanisms and microbicides, NICHD Seminar, NIH, Washington, USA, 2001

Sexual Transmission of HIV, National Center for AIDS Prevention and Control, Beijing, China, 2001

Cervical explant culture, an in vitro model of HIV transmission, Microbicides 2000, Washington, USA, 2000

HIV transmission, sex and the virus, Windeyer Institute of Medical Science, Royal Free and University College Medical School, London, UK, 1999

Antiviral factors and HIV replication in human monocytes, Center for Disease Control and Prevention, Atlanta, USA, 1999

Viral fitness and HIV transmission, Laboratory of Persistent Viral Diseases, National Institute of Allergy & Infectious Diseases, Rocky Mountain Laboratories, Montana, USA, 1999

Transduction signal for cytokine secretion and mycobacterial infection, 9th Congress of the Brazilian Association of Hansenology, Brazil, 1997

The role of macrophages in the pathogenesis of HIV disease, Center for Disease Control and Prevention, Atlanta, USA, 1996

Monocyte-T cell interaction regulates HIV replication in monocytic cells, 9th MRC HIV Workshop, Manchester, UK, 1995

Enhanced HIV replication in monocytic cells following engagement of adhesion molecules and contact with stimulated T cells, Franco-German Cooperation on AIDS Research, Frankfurt, Germany, 1995

Macrophages and HIV Pathogenesis, Department of Medicine, University Hospital, Geneva, Geneva, Switzerland, 1995

Monocyte adhesion regulates HIV transcription, 1st International Symposium on Cytokines and HIV, Reims, France, 1995

Regulation of HIV transcription in monocytic cells, Clinical Infection Society, London, UK, 1994

HIV infection of macrophages and cervical tissue, University of Wisconsin, Madison, USA, 1994

The effect of cell adhesion on HIV transcription and production in monocytic cells, Franco-German Cooperation on AIDS Research, Strasbourg, 1993

Target density dependency of non-neutralizing antibody-mediated HIV-1 inhibition and aggregation., Europrise "Antibodies Beyond Binding" Meeting, University of Strasbourg, 2011

Research Staff

Aldon,Y

Babaahmady,K

Chawda,M

Cope,A

Czyzewska-Khan,J

Evans,A

Harman,SJ

Herrera,C

Hu,Q

King,D

Makinde,J

McDonald,J

McKay,P

Olejniczak,N

Rogers,P

Serrano,M

Venables,S

Yan,C

Research Student Supervision

Badamchi-Zadeh,A

Cheeseman,H, Antibody Effector Functions Critical to Mucosal Protection to HIV-1

Kratochvil,S, Analysis of the phenome of vaccine antigen-induced B cell responses in humans

Okala,S, The impact of isotype and structure on antibody-HIV interaction